04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

AGS67E: Phase I data

Data from 30 patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) in an open-label, dose-escalation, North American Phase I trial showed that IV AGS67E every 3 weeks without growth factor...